Quotables
"Everyone acquainted with the subject will recognize it as a conspicuous failure."
Henry Morton, president of the Stevens Institute of Technology ; Said in 1880 about the light bulb
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7425340 | Permeation enhancing compositions for anticholinergic agents A transdermal or topical composition including anticholinergic agents, such as oxybutynin, a urea-containing compound and a carrier system. A method is disclosed for treating a subject for urinary incontinence while reducing the incidences of peak concentrations of ... | 09/16/2008 |
| 7320675 | Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure A drug delivery system detects a cardiac condition indicative of a need for increasing a cardiac metabolic level and, in response, releases a drug into tissue or blood to shift a source of metabolically synthesized energy fueling cardiac contraction from fatty acid ... | 01/22/2008 |
| 7250397 | Antiarrhythmic peptides Disclosed are novel peptides including antiarrhythmic peptides that have improved stability. Further disclosed are compositions that include such peptides and methods of using the compositions particularly as medicaments. ... | 07/31/2007 |
| 7177681 | Cardiac rhythm management system for edema A cardiac rhythm management system detects edema. In response to an episode of detected edema, it initiates or adjusts a cardiac resynchronization therapy and/or a cardiac contractility modulation (CCM) therapy. ... | 02/13/2007 |
| 7142911 | Method and apparatus for monitoring drug effects on cardiac electrical signals using an implantable cardiac stimulation device An implantable cardiac stimulation device, such as a pacemaker or Implantable Cardioverter Defibrillator, is configured to automatically monitor the effects of antiarrhythmic drugs on cardiac electrical signals within a patient to verify the efficacy of the drugs ta... | 11/28/2006 |
| 7089055 | Method and apparatus for delivering pre-shock defibrillation therapy An apparatus and method is presented for improving cardiac function after successful termination of a tachyarrhythmia such as ventricular fibrillation. A series of electrical stimulation pulses are delivered prior to a defibrillation shock if one or more specific cr... | 08/08/2006 |
| 7041303 | Use of moxonidine for postmyocardial infarction treatment A method of treating myocardial damage secondary to myocardial infarction using moxonidine or a physiologically compatible salt thereof. Pharmaceutical preparations containing moxonidine and its physiologically compatible acid addition salts are suitable for use in ... | 05/09/2006 |
| 6620836 | Antiarrhythmic and tranquilizer composition and treatment A composition employing a small amount of the hormone melatonin combined with a magnesium compound is formed into a lozenge or into a timed release tablet to act as an antiarrhythmic agent. As a lozenge to be dissolved in the mouth, it may incorporate mag... | 09/16/2003 |
| 6569460 | Film-coated tablet for improved upper gastrointestinal tract safety A novel oral dosage to be delivered to the stomach comprising a safe and effective amount of an active ingredient selected from the group consisting of emepronium bromidebromide, doxycycline, and other tetracyclines/antibiotics, iron preparations, quinidi... | 05/27/2003 |
| 6552033 | Imidazo-containing heterocyclic compounds, their compositions and uses The subject invention involves compounds having the structure: ##STR1## wherein each R1 is independently alkyl, aryl, or heterocycle; each R2-R7 is independently hydrogen or other substituent; B is nil and n is 0-3, or B is ethenyl and n is 0-1; and pharm... | 04/22/2003 |
| 6492382 | Dried or frozen pharmaceutical preparation containing a class III antiarrhythmic compound The present invention relates to dried preparations containing a class III antiarrhythmic compound in the form of a crystalline or amorphous salt or any combination thereof, where the counterion is selected from pharmaceutically acceptable water-soluble o... | 12/10/2002 |
| 6414030 | Use of benzenesulfonyl(thio)ureas for the treatment and prophylaxis of dysfunctions of the autonomous nervous system and use of benzenesulfonyl(thio)ureas in combination with beta-receptors blockers Substituted benzenesulfonylureas and -thioureas of the formula I ##STR1## in which R1, R2, E, X, Y and Z have the meanings described herein, show effects on the autonomous nervous system. The invention relates to the use of the compo... | 07/02/2002 |
| 6372783 | Enantiomeric compounds for treatment of cardiac arrhythmias and methods of use The subject invention pertains to novel enantiomerically pure compounds, and compositions comprising the compounds, for the treatment of cardiac arrhythmias. The subject invention further concerns a method of making and purifying the compounds. The isolat... | 04/16/2002 |
| 6369114 | Administration of an 댒-adrenergic receptor agonist to enhance cardiopulmonary resuscitation Methods, formulations and kits are described for resuscitating a patient suffering from cardiac arrest, for enhancing the efficacy of cardiopulmonary resuscitation, for treating post-resuscitation hypotension, and for reducing the incidence of ventricular... | 04/09/2002 |
| 6362223 | Enantiomeric compounds for treatment of cardiac arrhythmias and methods of use The subject invention pertains to novel enantiomerically pure compounds, and compositions comprising the compounds, for the treatment of cardiac arrhythmias. The subject invention further concerns a method of making and purifying the compounds. The enanti... | 03/26/2002 |
| 6333337 | Potassium channel inhibitors Compounds useful as potassium channel inhibitors and especially useful for the treatment of cardiac arrhythmias and cell proliferative disorders are described.... | 12/25/2001 |
| 6221401 | Bilayer structure which encapsulates multiple containment units and uses thereof The present invention provides a bilayer structure for encapsulating multiple containment units. These containment units can attach or contain therapeutic or diagnostic agents that can be released through the bilayer structure. A suitable example of such ... | 04/24/2001 |
| 6214809 | Methods of treating or preventing cardiac arrhythmia A method of treating or preventing supraventricular tachyarrhythmias is disclosed which comprises the use of a compound which selectively blocks the ultra-rapidly-activating delayed rectifier K+ current (IKur) of the human atrium.... | 04/10/2001 |
| 6214810 | Methods of treating or preventing cardiac arrhythmia This application discloses a method of treating or preventing atrial arrhythmias which utilizes compounds which are blockers of the ultra-rapidly-activating delayed rectifier K+ current (IKur) of the human atrium in a use-dependent a... | 04/10/2001 |
| 6174873 | Oral administration of adenosine analogs Disclosed are compositions including an adenosine analog, wherein the composition comprises a dosage form suitable for oral (co)administration. Also disclosed are compositions including adenosine analogs, wherein the composition is in a dosage form includ... | 01/16/2001 |
| 6124363 | Dofetilide polymorphs The invention relates to the substantially pure dofetilide polymorphs P162, P162a and P143, and to processes for the preparation of, compositions containing and to the uses of, such polymorphs.... | 09/26/2000 |
| 6090852 | Substituted alpha-aminosulphonyl-acetohydroxamic acids as therapeutic agents Compounds of formula (I): ##STR1## where the substituents are as defined herein, and salts thereof, are matrix metalloprotease inhibitors.... | 07/18/2000 |
| 6071953 | Sulfonamide-substituted chromans, processes for their preparation, their use as medicament or diagnostic aid, and medicament comprising them Chromans of formula I ##STR1## with the meanings of R(A), R(B) and R(1) to R(8) stated in the specification are suitable for producing a medicament for blocking the K+ channel that is opened by cyclic adenosine monophosphate (cAMP); ... | 06/06/2000 |
| 6057322 | Basically-substituted benzoylguanidines, a process for preparing them, their use as a medicament or diagnostic agent, and a medicament containing them Compounds of the formula I ##STR1## and the pharmaceutically tolerated salts thereof, are described. A process for their preparation and their use as medicaments in cardiovascular diseases are also described.... | 05/02/2000 |
| 6043259 | Treatment of cardiovascular and related pathologies Compositions and methods for treatment and prevention of hypertrophy, hypertension, congestive heart failure, ischemic heart disease, ischemia-related conditions, such as ischemia reperfusion injury and cellular dysfunction, are described. The methods are... | 03/28/2000 |
| 6025349 | Phenyl.-substituted alkenylcarboguanidides carrying perfluoroalkyl groups, a process for their preparation, their use as a medicament or diagnostic agent, and also a medicament containing them Phenyl-substituted alkenylcarboguanidides carrying perfluoroalkyl groups, a process for their preparation, their use as a medicament or diagnostic agent, and also a medicament containing them. Phenyl-substituted alkenylcarboguanidides carrying perfluoroalkyl g... | 02/15/2000 |
| 6013674 | Cell adhesion inhibitors This invention provides novel indenone derivatives, their pharmaceutical formulations and their use for the inhibition of leukocyte adherence to cells.... | 01/11/2000 |
| 6005010 | Phenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them Compounds of the formula ##STR1## where T is ##STR2## and R(A), R(B), R(C), R(D), R(E), R(F), x and y have the meanings indicated in the claims, and their pharmaceutically acceptable salts are effective inhibitors of the cellular sodium-pro... | 12/21/1999 |
| 6001881 | Ortho-substituted benzoylguanidines, a process for their preparation, their use as a medicament or diagnostic agent, and a medicament comprising them Benzoylguanidines of the formula I ##STR1## in which: R(1) to R(4) have the meanings given in the claims, are antiarrhythmic pharmaceuticals, having a cardioprotective component, which are also valuable for the prevention of ischemically induced dama... | 12/14/1999 |
| 5998387 | Method for using A1 adenosine receptor agonists Adenosine and xanthine deriviatives, and compositions comprising those compounds, are potent selective agonists of adenosine receptors. The derivatives and compositions are used to treat conditions, including certain cardiac arrhythmias.... | 12/07/1999 |
| 5977177 | Substituted benzenesulfonylureas and-thioureas, processes for their preparation and use of pharmaceutical preparations based on these compounds, and medicaments containing them This invention relates to substituted benzenesulfonylureas and -thioureas, processes for their preparation and use of pharmaceutical preparations based on these compounds, and medicaments containing them. Substituted benzenesulfonylureas and -thioureas of the ... | 11/02/1999 |
| 5932246 | Therapeutic uses of verapamil enantiomers Substantially single enantiomer (R or S) verapamil, or a pharmaceutically-acceptable salt thereof provides an improved treatment for patients having a condition susceptible to treatment with racemic verapamil and who are disposed to constipation.... | 08/03/1999 |
| 5929071 | Method for the treatment of preterm labor The invention is directed to a method useful in the treatment of preterm labor, dysmenorrhea and for the stoppage of labor preparatory to cesarean delivery.... | 07/27/1999 |
| 5900436 | Substituted indanylidineacetylguanidines, processes for their preparation, their use as medicaments or diagnostics and medicaments containing them Substituted Indanylidineacetylguanidines, process for their preparation, their use as medicaments or diagnostic and medicaments containing them: Indanylidineacetylguanidines I ##STR1## and their pharmaceutically acceptable salts wherein R1, R2, R3, R4, R5... | 05/04/1999 |
| 5883133 | Substituted cinnamic acid guanidides, a process for their preparation, their use as medicaments or diagnostic agents and medicaments comprising them Compounds of the formula I ##STR1## are described in which at least one of the substituents R(1), R(2), R(3), R(4) and R(5) is a nitrogen-containing heterocyclic radical. They are outstanding cardiovascular therapeutic agents. They are obtained by ... | 03/16/1999 |
| 5876747 | Liposome preferentially traveling to cardiac and skeletal muscles Carnitine, aminocarnitine and cysteic acid serve as carriers to bring pharmaceutically active compounds to desired sites in the body, e.g. skeletal muscle or the heart. The pharmaceutically active compound can be a protease inhibitor, a cardioactive drug ... | 03/02/1999 |
| 5876756 | Microcapsule containing amorphous water-soluble 2-piperazinone-1-acetic acid compound A microcapsule contains a pharmaceutically effective amorphous water-soluble 2-piperazinone-1-acetic acid compound or salt thereof and a polymer binder and a method of preparing said microcapsule. The microcapsule is produced by dispersing in an aqueous p... | 03/02/1999 |
| 5874475 | Antiarrhythmic (S)-enantiomers of methanesulfonamides Compounds of formula (I) and pharmacologically acceptable salts thereof wherein: n is 1 to 3, R is an alkyl, R1 is hydrogen or alkyl, R2 is alkyl, R3 is an alkyl; b) alkyl substituted with an aryl, heteroaryl or cycloalkyl... | 02/23/1999 |
| 5866610 | Substituted benzoylguanidines, process for their preparation, their use as a pharmaceutical as inhibitors of the cellular NA+/H+ exchange or as a diagnostic, and pharmaceutical containing them Substituted benzoylguanidines, process for their preparation, their use as a pharmaceutical or diagnostic, and pharmaceutical containing them. Described are benzoylguanidines of the formula I ##STR1## where R(1) to R(3) are H, Hal, (cyclo)alkyl, N3 | 02/02/1999 |
| 5855892 | Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease A method of altering the concentration of cholesterol constituents in human blood is provided. A daidzein material is administered to a human to increase the concentration of HDL-cholesterol and to decrease the level of LDL-cholesterol in the blood. The d... | 01/05/1999 |
